Association of extreme age with worse survival in advanced breast cancer.

e11530 Background: Age has been associated with survival in advance breast cancer. In the ALAMO Register prognostic index, older age was associated with mortality. Although recent reports suggest that age below 35 was also associated with worse prognosis. We analysed the impact of extreme ages in survival in an advance breast cancer cohort. Methods: Survival analysis of patients followed in the Advance Breast Cancer Cohort at the Reina Sofia Hospital between 1996-2006. Patients were classified in 4 groups of age: I (< 35), II (35-50), III (51-75) and IV (>75 years). Log-rank test was used to compare survivals between groups. Cases were censored after 5 years of follow-up. A uni and multivariate stepwise regression model was used to estimate factors associated with survival. Results: 212 cases of advance breast cancer were included. Patients’ main characteristics, distributed by age groups, are reported in the Table. Median (IQR) survival was shorter (p=0.01) in group I 12.4 (4.7-25.4) and group IV 10.8 (5.1-19.8) compared to groups II 23.5 (17-29.5) and group III 20.2 (15.2-23.7). Factors independently associated with survival were age groups 1-4 versus 2-3 (p=0.02), histologic grade II-II versus I-unknown (<0.01), disease free interval <24 months versus >24 months (p<0.01) and visceral versus non-visceral metastatic location (p<0.01). Conclusions: Extreme ages (<35 or >75 years) at the diagnosis of the advance breast cancer are associated with worse survival. This factor in addition with the histologic grades, the disease free interval and metastatic location were associated with survival. [Table: see text]

Download Full-text

Pulmonary resection and systemic lymph node dissection in a patient with breast cancer who had a 33-year disease-free interval

World Journal of Surgical Oncology ◽

10.1186/s12957-015-0565-y ◽

2015 ◽

Vol 13 (1) ◽

Author(s):

Degang Yin ◽

Guofei Zhang ◽

Lufeng Zhao ◽

Ying Chai

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Lymph Node Dissection ◽

Pulmonary Resection ◽

Node Dissection ◽

Disease Free Interval ◽

Free Interval ◽

Disease Free

Download Full-text

Oestrogen and progesterone receptors and disease-free interval in primary breast cancer

British Journal of Cancer ◽

10.1038/bjc.1984.234 ◽

1984 ◽

Vol 50 (5) ◽

pp. 667-672 ◽

Cited By ~ 33

Author(s):

A Alanko ◽

E Heinonen ◽

T M Scheinin ◽

E M Tolppanen ◽

R Vihko

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Progesterone Receptors ◽

Disease Free Interval ◽

Free Interval ◽

Disease Free

Download Full-text

HER-2 status of the primary breast cancer in patients with relapse at least five years after the initial diagnose

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.10631 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 10631-10631

Author(s):

Z. I. Tomasevic ◽

D. Jovanovic ◽

L. Radosevic-Jelic ◽

Z. Tomasevic ◽

S. Vasovic ◽

...

Keyword(s):

Breast Cancer ◽

Breast Carcinoma ◽

Contralateral Breast ◽

Late Relapse ◽

Primary Breast Carcinoma ◽

Disease Free Interval ◽

Free Interval ◽

Her 2 ◽

Time To Relapse ◽

Disease Free

10631 Background: HER-2 status of the primary breast carcinoma in the subgroup of patients who relapsed after many years is not well known. The aim of this paper is to determine the HER-2 status of the primary breast cancer in patients with late relapse, defined as local recurrence, distant metastases or carcinoma in the contralateral breast, at least five years after the initial diagnosis Methods: During six month period (June-November 2005) 1256 patients were diagnosed with primary or relapsed breast cancer at the IORS. HER-2 (HercepTest, DAKO) status was determined on the archived pathological specimens of patients with late relapse. Results: One hundred eleven patients (111/1256; 8,8%) were diagnosed with late relapse. At the time of the initial diagnose, majority of patients have been treated for early breast carcinoma. Median age at the initial diagnose was 50 years (33–74). Initial tumor characteristic were: ductal carcinoma 49%; lobular carcinoma 41%;cancer mastitis 6,5%;not reported 3,5%; T1 34%; T2 52%; T3 4,5%; T4 6%;unknown 3,5%; Nodal status: positive 73,5%; negative 23%;not reported 3,5% Steroid receptor status: ER and/or PR positive 59%; both negative 14%; unknown 27%. Median time to relapse is 7 years, (range 5–29), the most frequent first relapse sites were: local recurrence (22%); carcinoma of the contralateral breast (18%); bone metastases (18%). Archived pathological specimens are identified for 63/111 (56,7%) patients and HER-2 status of the those primary breast carcinoma is: 0+ 36,5%; 1+ 34,9%; 2+ 9,5%; 3+ 14,2%; Thirty four patients (30,6%) had disease free interval 10 or more years, and HER-2 3+ in this subgroup is 17,6% (6/34). Conclusions: Long disease free interval in breast cancer patients is usually explained by initial more favorable cancer characteristics. Still, a significant percentage (14,2%) of our patients with median time to relapse of 7 years, initially had breast cancers with HER-2 3+. No significant financial relationships to disclose.

Download Full-text